Clinical Trial

Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 5, 2024 (before its estimated December 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study evaluated the clinical benefits of intravenous administration of pyrotinib combined with trastuzumab subcutaneous preparation by comparing the efficacy and quality of life of intravenous administration in the treatment of HER2-positive early breast cancer
Trial Details
NCT Number NCT06537674
Lead Sponsor Jiangsu Famous Medical Technology Co., Ltd.
Conditions HER2+ Breast Cancer
Enrollment 100 participants
Start Date 2024-08-15
Primary Completion 2025-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-05